The REMIND Study- SPARK Neuro Software Study

Prior treatment

• Subjects currently on and unable to wash out concomitant medications, including: 1) opiates; 2) benzodiazepines and nonbenzodiazepine hypnotics; 3) sedative antihistamines; 4) tricyclic anti-depressants; 5) skeletal muscle relaxants; 6) antiepileptics; 7) antipsychotics; 8) antimanic agents; 9) THC; 10) anticholinergics
• Previous history of craniotomy
• Subject meets at least one of the following criteria:
  • Diagnosis of cognitive impairment from various underlying pathologies as indicated by one of the diagnostic codes listed in Appendix A (protocol)
  • MMSE score of 27 or less
  • Treating physician or PI have documented that the patient is cognitively impaired, with judgment of cognitive impairment having been made within the 6 months prior to enrollment

Other illness

• Medical or psychiatric illness that would interfere with study participation
• History of epilepsy or chronic seizure disorder
• Currently experiencing a skin disease on scalp that would affect electrode contacts
• Substance Use Disorder, including Alcohol

Other

• Unable to remain still for up to 30 minutes during EEG data recording
• Presence of non-dental metal in head

• Age 55 to 85 at the time of consent
• Informant available and willing (remotely or in-person) to provide information about sleep patterns and cognitive functioning who spends \>8 hours per week with primary subject
• Subject or Legally Authorized Representative (LAR) has the ability to provide informed consent and comply with the protocol.